Maladies inflammatoires chroniques de l'intestin et phenomenes thromboemboliques veineux.

Humans; Inflammatory Bowel Diseases/complications; Risk Factors; Venous Thromboembolism/etiology/prevention & control; Coagulation; Venous Thrombosis; Inflammatory Bowel Disease; Pulmonary Embolism

Abstract :

[en] Inflammatory Bowel Diseases (IBD) are associated with lots of extra-intestinal complications. Among them, venous and arterial thromboembolisms lead to high rates of morbidity and mortality. They often occur during an IBD flare and seem to be mostly provoked by acquired factors. The prevention mainly resorts to heparin, which is not used enough in spite of its effectiveness. Its indications have recently been upgraded to outpatients. In this review, we describe the epidemiological and aetiological features of these manifestations, as well as their prevention and management. Only venous thromboembolisms are considered.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

DELHOUGNE, Nicolas ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Département de médecine interne

COLARD, Arnaud ; Centre Hospitalier Universitaire de Liège - CHU > Département de médecine interne > Service de gastroentérologie, hépatologie, onco. digestive

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

Language :

French

Title :

Maladies inflammatoires chroniques de l'intestin et phenomenes thromboemboliques veineux.

Alternative titles :

[en] Inflammatory bowel disease and venous thromboembolisms

Publication date :

2018

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

462-467

Peer reviewed :

Peer reviewed

Additional URL :

https://www.rmlg.ulg.ac.be

Available on ORBi :

since 19 May 2020

Statistics

Number of views

74 (6 by ULiège)

Number of downloads

9 (5 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Murthy SK, Nguyen GC.- Venous thromboembolism in inflammatory bowel disease: an epidemiological review. Am J Gastroenterol, 2011, 106, 713-718.
Yuhara H, Steinmaus C, Corley D, et al.- Meta-analysis: the risk of venous thromboembolism in patients with inflammatory bowel disease. Aliment Pharmacol Ther, 2013, 37, 953-962.
Fumery M, Xiaocang C, Dauchet L, et al.- Thromboembolic events and cardiovascular mortality in inflammation bowel diseases: a meta-analysis of observationnal studies. J Crohns Colitis, 2014, 8, 469-479.
Kuy SR, Dua A, Chappidi R, et al.- The increasing incidence of thromboembolic events among hospitalized patients with inflammatory bowel disease. Vascular, 2015, 23, 260-264.
Alatri A, Schoepfer A, Fournier N, et al.- Prevalence and risk factors for venous thromboembolic complications in the Swiss Inflammatory Bowel Disease cohort. Scand J Gastroenterol, 2016, 51, 1200-1205.
Grainge MJ, West J, Card TR.- Venous thromboembolism during active disease and remission in inflammatory bowel disease: a cohort study. Lancet, 2010, 375, 657-663.
Papay P, Miehsler W, Tilg H, et al.- Clinical presentation of venous thromboembolism in inflammatory bowel disease. J Crohns Colitis, 2013, 7, 723-729.
Nguyen GC, Sam J.- Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol, 2008, 103, 2272-2280.
Kappelman MD, Horvath-Puho E, Sandler RS, et al.- Thromboembolic risk among Danish children and adults with inflammatory bowel diseases: a population-based nationwide study. Gut, 2011, 60, 937-943.
Novacek G, Weltermann A, Sobala A, et al.- Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology, 2010, 139, 779-787.
Koutroubakis IE, Sfiridaki A, Tsialokidou G, et al.-Genetic risk factors in patients with inflammatory bowel disease and vascular complications: case-control study. Inflamm Bowel Dis, 2007, 13, 410-415.
Bernstein CN, Sargent M, Vos HL, et al.- Mutations in clotting factors and inflammatory bowel disease. Am J Gastroenterol, 2007, 102, 338-343.
Spina L, Saibeni,S, Battaglioli T, et al.- Thrombosis in inflammatory bowel diseases: role of inherited thrombophilia. Am J Gastroenterol, 2005, 100, 2036-2041.
Tsialokidou G, Koutroubakis IE.- Thrombosis and inflammatory bowel disease-the role of genetic risk factors. World J Gastroenterol, 2008, 14, 4440-4444.
Nguyen GC, Bernstein CN, Bitton A, et al.-Consensus statements on the risk, prevention, and treatment of venous thromboembolism in inflammatory bowel disease: Canadian Association of Gastroenterology. Gastroenterology, 2014, 146, 835-848.
Danese S, Papa A, Saibeni S, et al.- Inflammation and coagulation in inflammatory bowel disease: The clot thickens. Am J Gastroenterol, 2007, 102, 174-186.
Yoshida H, Granger DN.- Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis, 2009, 15, 1245-1255.
Yoshida H, Russell J, Senchenkova EY, et al.-Interleukin-1 mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol, 2010, 177, 2774-2781.
Yan SL, Russel J, Granger DN.- The platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis, 2014, 20, 353-362.
Yoshida H, Yilmaz CE, Granger DN.- Role of tumor necrosis factor-α in the extraintestinal thrombosis associated with colonic inflammation. Inflamm Bowel Dis, 2011, 17, 2217-2223.
Miehsler W, Reinisch W, Valic E, et al.- Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism? Gut, 2004, 53, 542-548.
Solem CA, Loftus EV, Tremaine WJ, et al.- Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol, 2004, 99, 97-101.
Sipeki N, Davida L, Palyu E, et al.- Prevalence, significance and predictive value of antiphospho-lipid antibodies in Crohn's disease. World J Gastroenterol, 2015, 21, 6952-6964.
Oussalah A, Guéant JL, Peyrin-Biroulet L.- Meta-analysis: hyperhomocysteinaemia in inflammatory bowel diseases. Aliment Pharmacol Ther, 2011, 34, 1173-1184.
Den Heijer M, Koster T, Blom HJ, et al.- Hyperho-mocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med, 1996, 334, 759-762.
Wallaert JB, DeMartino RR, Marsicovetere PS, et al.- Venous thromboembolism after surgery for inflammatory bowel disease: are there modifiable risk factors? Data from ACS NSQIP. Dis Colon Rectum, 2012, 55, 1138-1144.
Senchenkova E, Seifert H, Granger DN.- Hyper-coagulability and Platelet Abnormalities in Inflammatory Bowel Disease. Semin Thromb Hemost, 2015, 41, 582-589.
Bollen L, Vandecasteele N, Peeters M, et al.-Short-term effect of infliximab is reflected in the clot lysis profile of patients with inflammatory bowel disease: a prospective study. Inflamm Bowel Dis, 2015, 21, 570-578.
Higgins PD, Skup M, Mulani PM, et al.- Increased risk of venous thromboembolic events with corticosteroid vs biologic therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol, 2015, 13, 316-321.
Masson PL.- Thromboembolic events and anti-tumor necrosis factor therapies. Int Immunophar-macol, 2012, 14, 444-445.
Turpie AG.- Thrombosis prophylaxis in the acutely ill medical patient: insights from the prophylaxis in MEDical patients with ENOXaparin (MEDENOX) trial. Am J Cardiol, 2000, 86, 48M-52M.
Hull RD, Schellong SM, Tapson VF, et al.-Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med, 2010, 153, 8-18.
Ananthakrishnan AN, Cagan A, Gainer VS, et al.-Thromboprophylaxis is associated with reduced post-hospitalization venous thromboembolic events in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol, 2014, 12, 1905-1910.
Tinsley A, Naymagon S, Trindade AJ, et al.- A survey of current practice of venous thromboembolism prophylaxis in hospitalized inflammatory bowel disease patients in the United States. J Clin Gastroenterol, 2013, 47, e1-6.
Shen J, Ran ZH, Tong JL, et al.- Meta-analysis: the utility and safety of heparin in the treatment of active ulcerative colitis. Aliment Pharmacol Ther, 2007, 26, 653-663.
Harbord M, Annese V, Vavricka SR, et al.- The First european Evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease. J Crohns Colitis, 2016, 10, 239-254.
Yeh CH, Gross PL, Weitz JI.- Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood, 2014, 124, 1020-1028.
Nguyen GC, Sharma S.- Feasibility of venous thromboembolism prophylaxis during inflammatory bowel disease flares in the outpatient setting: a decision analysis. Inflamm Bowel Dis, 2013, 19, 2182-2189.
Mowat C, Cole A, Windsor A, et al.- Guidelines for the management of inflammatory bowel disease in adults. Gut, 2011, 60, 571-607.
Kornbluth A, Sachar DB.- Practice parameters committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, practice parameters Committee. Am J Gastroenterol, 2010, 105, 501-523.
Nguyen GC, Bernstein CN.- Duration of anticoagulation for the management of venous thromboembolism in inflammatory bowel disease: a decision analysis. Am J Gastroenterol, 2013, 108, 1486-1495.
Koutroubakis IE.- The relationship between coagulation state and inflammatory bowel disease: current understanding and clinical implications. Expert Rev Clin Immunol, 2015, 11, 479-488.